



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/823,649	03/30/2001	Edward Soh Smith	022101-001800US	8561
41504	7590 04/15/2005		EXAMINER	
TOWNSEND AND TOWNSEND AND CREW, LLP			GOLDBERG, JEANINE ANNE	
	ADERO CENTER, 8TI CISCO, CA 94111	H FLOOR	ART UNIT	PAPER NUMBER
	<b>,</b>		1634	
			DATE MAILED: 04/15/200:	5

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/823,649	SMITH ET AL.			
		Examiner	Art Unit			
		Jeanine A. Goldberg	1634			
Period fo	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum story period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠	1) Responsive to communication(s) filed on <u>27 January 2005</u> .					
2a)□	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.					
3)□	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Dispositi	ion of Claims					
4)⊠ Claim(s) <u>13-16,20-24,27-32,36-44 and 48-52</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
	5) Claim(s) is/are allowed.					
6)⊠	Claim(s) 13,20-24,27-29,36-41 and 48-52 is/ar	e rejected.	,			
	7) Claim(s) <u>14-16,30-32,42-44</u> is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.						
Applicati	on Papers					
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	ınder 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1.☐ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
3) 🔲 Inform						
Paper No(s)/Mail Date 6) U Other:						

U.S. Patent and Trademark Unit PTOL-326 (Rev. 1-04) Application/Control Number: 09/823,649

### **DETAILED ACTION**

- 1. This action is in response to the papers filed January 27, 2004. Currently, claims 13-16, 20-24, 27-32, 36-44, 48-52 are pending.
- 2. All arguments have been thoroughly reviewed but are deemed non-persuasive for the reasons which follow.
- 3. Any objections and rejections not reiterated below are hereby <u>withdrawn</u> in view of applicant's arguments.
  - a. It is clear from the amendments to the claims and from the arguments that the claims do not require SEQ ID NO: 2, 3, 4, for example but rather require an enzyme which has been altered from this sequence.

### **Priority**

4. This application claims priority to provisional application 60/198,336, filed April 18, 2000.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 5. Claims 13, 20-24, 27-30, 36-42, 48-52 are rejected under 35 U.S.C. 102(b) as being anticipated by Bergquist et al (WO 95/14770, June 1995).

Art Unit: 1634

Bergquist teaches SEQ ID NO: 1, 2, 14 of the instant application. Bergquist teaches that the invention comprises a thermophilic enzyme which is used in PCR and RT/PCR amplifications (limitations of Claims 20, 36, 48). All PCR reactions were performed in Tris-HCL, MgCl2 with nucleotides, primers and DNA polymerase and template (page 12). Bergquist teaches that the reverse transcriptions were performed at 60C and allowed to proceed (page 12)(limitations of Claim 23, 39, 51). Bergquist teaches that Taq polymerase and Tth polymerase require Mn2+. Tfil polymerase shows the same high level of reverse transcriptase activity as Tth pol but differs in that no activity is obtained when MnCl2 was used instead of MgCl2 for reverse transcription (page 18). The polymerase is taught to be useful in RT-PCR assays.

Bergquist teaches that the polymerase comprises **LSDRIHLLHPE**. This polymerase comprises an amino acid sequence of L[SA].[-EAGP][LI].....E as required by Claim 13, 29, 41. The amino acid sequence is located in Figure 1-1 on the line beginning with 421 (limitations of Claim 13).

#### Response to Arguments

This argument has been thoroughly reviewed but is not found persuasive because Bergquist specifically teaches a polymerase comprising LSDRIHLLHPE. This polymerase comprises an amino acid sequence of L[SA].[-EAGP][LI].....E as required by Claim 13, 29, 41. The amino acid sequence is located in Figure 1-1 on the line beginning with 421 (limitations of Claim 13). Bergquist teaches a polymerase comprising the mutant domain.

Application/Control Number: 09/823,649

Art Unit: 1634

The response asserts that "it is doubtful that the authors discovered the reverse transcriptase activity" (page 8 of response filed January 27, 2005). The response asserts that primer T7 is not complementary to alpha-lactalbumin mRNA. This argument has been thoroughly reviewed but is not found persuasive because while the response characterizes the references as saying that either P3 or T7 were used as the forward primer, Bergquist does not appear to say this. Bergquist states, "RT/PCR amplifications had the initial reverse transcription performed in a reaction volume of 25ml and contain 50nM Tris-HCl buffer pH 8.8, 2 mM MgCl2, 0.05% Tween 20, 0.05% Nonidet P40, 400 mM of each dNTP, and 100 ng of reverse primer P1 or p2. The amount of enzyme used was varied between 1 and 5 units, and often, the forward primer T7 or P3, which are necessary for the PCR amplification step was also included in the reverse transcription mixture." (page 12). The arguments provided by attorney do not appear to consider the full teachings of the reference. The reference is directed to forward primer T7 or P3, however, the response fails to review the full scope of the reference. On page 18, Bergquist specifically discusses reverse transcriptase activity. Figure 7 and 8 are directed to experimental results. The results of Figure 7 are reverse transcription and thus, it is clear that reverse transcription and PCR amplification with as little as 32 pg of template RNA is successful (page 21).

Page 4

#### Conclusion

6. **No claims allowable.** Claims 14-16,30-32,42-44 are objected to as being dependant on non-allowable claims.

Application/Control Number: 09/823,649

Art Unit: 1634

Page 5

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jeanine Goldberg whose telephone number is (571) 272-0743. The examiner can normally be reached Monday-Friday from 7:00 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (571) 272-0745.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The Central Fax Number for official correspondence is (571) 273-8300.

**Primary Examiner** April 11, 2005